FindTrial
Sign In

Effect of Some Drugs on Liver Fibrosis

Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03770936
Enrollment
45
Registered
2018-12-10
Start date
2018-10-01
Completion date
2027-11-30
Last updated
2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Fibroses

Brief summary

Effect of Some Drugs on Liver Fibrosis

Detailed description

The study aimed at evaluating the effect of Some Drugs on Liver Fibrosis

Interventions

DRUGCandesartan

Candesartan 8 mg/day

DRUGRamipril

ramipril 1.25 mg/day

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* chronic hepatitis C

Exclusion criteria

* Acute hepatitis * Thalassemia

Design outcomes

Primary

MeasureTime frameDescription
Change in Fibroscan or APRI score6 monthsChange in Fibroscan or APRI score

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, Ph D
sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026